My goal is to beat the market, I'm still relatively young and want to see if I can do it, if not I'll put everything in an etf in 5 years.

Regarding my portfolio, I currently have a cash ratio of 23-25% depending on the fluctuations in the last month.

Purchases of existing stocks:

I plan to increase the financial stocks by 50%, $CG (-6,35 %)
$KKR (-8,88 %)
$APO (-11,14 %)
$TPG (-2,87 %) .

In addition, a little $DMP (-1,73 %) by 25%.

Sales:

I made the mistake of wanting to $EVO (-3,87 %) and $CPRX (-3,53 %) trade, but then I was too greedy.

I am convinced of both positions in the long term but not in this size in the portfolio, which is why I will reduce both stocks by 33%.

Potential purchases:

$HALO (-4,49 %)
$CUV (-6,63 %) - Will invest a little extra, otherwise just the 33% from sale of $CPRX. Both around 50 - 50

$SL (-3,92 %) - the same as $TISG (-3,89 %)

$KSPI (-7,6 %) - about as high as $MUM (-2,51 %)

$FIH.U (-4,98 %) - about as high as $MUM (-2,51 %)

$2GB (-6,57 %) - about as high as $MUM (-2,51 %)

$M12 (-8,96 %) - about as high as $MUM (-2,51 %)

$CPR (-3,53 %)
$DGE (-1,41 %)
$RI (-3,46 %) - I'll wait and see, but I can imagine that they will develop in a similar way to the tobacco shares. Since I don't want to decide, I'll just buy three for the sum of one. And divide the amount between these 3.

In general:

I'm generally a fan of putting together baskets like with alcohol or the yacht builders.

What would you change because you see a high risk? I am relatively poorly positioned in the tech sector, do you have any other titles that I could take a closer look at in this area?

Masterflex SE presents Annual Report 2024 + Dermapharm increases revenue and exceeds EBITDA forecast + Demand remains unbroken at CTS EVENTIM + Secunet Security Networks plans further growth

Masterflex SE $MZX (-6,92 %)presents annual report 2024

• Record operating result achieved despite challenging economic environment
• Group revenue at EUR 98.1 million (previous year: EUR 101.1 million)
• Record EBITDA of EUR 18.2 million (previous year: EUR 17.9 million) and operating EBIT of EUR 12.7 million (previous year: EUR 12.6 million) achieved
• Operating EBIT margin improved again to 13.0% (previous year: 12.4%)
• Balance sheet quality significantly improved with an equity ratio of 67.7% (previous year: 61.5%)
• Dividend of EUR 0.27 per share planned for 2024 (previous year: EUR 0.25)
• Liabilities to banks reduced by 25%
• Forecast for 2025: sales of EUR 100 million to EUR 105 million and EBIT of between EUR 12 million and EUR 15 million expected

Dermapharm $DMP (-1,73 %)increases sales and exceeds EBITDA forecast

• Group sales increase by 4.0 % to EUR 1,180.8 million
• Group EBITDA (unadjusted) increases by 10.2 % to EUR 308.9 million, unadjusted EBITDA margin is 26.2
• EBITDA (adjusted) of EUR 315.6 million corresponds to an adjusted EBITDA margin of 26.7 %, the adjustments of EUR 6.7 million are significantly lower than in 2023
• For the current financial year, Dermapharm expects further adjusted EBITDA growth at Group level to EUR 322 million to EUR 332 million with revenue of EUR 1,160 million to EUR 1,200 million and an improved EBITDA margin
• The Management Board will propose to the Annual General Meeting the payment of a dividend of 90 cents per share for the past financial year

At CTS EVENTIM $EVD (-2,57 %)demand is unbroken

• Demand is unbroken, says Eventim CEO Klaus-Peter Schulenberg to the Frankfurter Allgemeine Zeitung (FAZ).
• "Eventim will continue to grow this year and is aiming for double-digit growth."
• With an adjusted EBITDA margin of 6.4 percent in the live sector, the company is a leader among global providers.
• "A year-on-year comparison is always difficult.
• Fluctuations are also related to the fact that event expenses are booked as costs long before the events.
• Income, on the other hand, is only booked after the event has taken place.
• Fluctuations are therefore inevitable.
• As a rule, however, we should achieve a margin of between 6 and 8 percent."
• The cost curve is flattening somewhat, while on the revenue side, efforts are being made to keep the base prices for group tickets stable.

Secunet Security Networks $YSN (-9,92 %)wants to grow further

• The IT security company Secunet Security Networks wants to continue to grow in the current year.
• The company, which has been listed on the small-cap index SDax since the beginning of the week, announced on Friday that turnover is set to increase by just under five percent to around 425 million euros.
• The profit margin before interest and taxes should be between 9.5 and 11.5 percent.
• The market environment remains challenging, particularly in the public sector in Germany, due to the formation of a government following the federal elections.
• However, the order backlog at the beginning of the year is already higher than in the previous year.
• In addition, Secunet CEO Axel Deininger expects demand for security solutions to remain strong, "which should be particularly visible in the second half of the year."
• Secunet confirmed preliminary figures for the past year.
• Turnover rose from 393.7 million euros in the previous year to 406.4 million euros.
• At 42.5 million, earnings before interest and taxes (EBIT) were just below the previous year's level.
• The operating margin amounted to 10.5 percent.
• Below the line, Secunet earned 27.9 million euros after 29.0 million euros in 2023.
• Secunet had already announced a change of CEO in the coming year last Wednesday.
• Deininger's contract will not be extended beyond the regular expiry date of December 31, 2025.
• Marc-Julian Siewert is to be appointed to the Management Board from July and will then also be Deininger's designated successor.
• Secunet claims to be Germany's leading cybersecurity company and specializes in cloud security, among other things.
• Secunet's customers include federal ministries and more than twenty DAX-listed companies.

Friday: Stock market dates, economic data, quarterly figures

• ex-dividend of individual stocks
• Sartorius Vz. 0.74 EUR
• Sartorius St. EUR 0.74
• Swisscom 22.00 CHF
• British American Tobacco USD 0.75

• Quarterly figures / Company dates Europe
• 06:45 Basler annual result
• 07:30 Dermapharm | Dürr | GFT Technologies | Sixt Annual results
• 07:55 Energiekontor annual results
• 08:00 Secunet Security | Wüstenrot & Württembergische Annual results/
• 09:00 Wüstenrot & Württembergische Analyst Conference
• 11:00 Basler Investor Conference | HSBC Holdings Extraordinary General Meeting
• 13:00 Holcim Capital Markets Day
• 18:00 Deutsche Euroshop Annual Results

• Economic data

08:00 DE: GfK consumer climate indicator FORECAST: -22.5 points previously: -24.7 points | Employment February

08:00 UK: GDP (2nd release) 4Q PROGNOSE: +0.1% yoy/+1.4% yoy | Trade Balance January PROGNOSE: n.a. previous: -17.4 bn GBP

08:45 FR: Private consumption February FORECAST: n/a previous: -0.5% yoy/+0.4% yoy | Consumer prices (preliminary) March FORECAST: +0.4% yoy/+1.0% yoy previous: 0.0% yoy/+0.8% yoy

09:00 ES: HICP and consumer prices (preliminary) March HICP PROGNOSIS: n/a previous: +2.9% yoy

09:55 DE: Labor market data March seasonally adjusted unemployment rate FORECAST: +10,000 yoy previously: +5,000 yoy Unemployment rate seasonally adjusted FORECAST: 6.2% previously: 6.2%

10:00 EU: ECB, February consumer survey results

11:00 EU: Economic Sentiment Index March Eurozone Economic Sentiment Forecast: 97.0 Previous: 96.3 Industrial Confidence Eurozone Forecast: -10.6 Previous: -11.4 Consumer Confidence Eurozone Advance Estimate: -14.5 Previous: -13.6| Business Climate Index Eurozone March

13:30 US: Personal Spending and Income February Spending / Income FORECAST: +0.5% yoy/+0.4% yoy previous: -0.2% yoy/+0.9% yoy PCE Price Index / Total Rate FORECAST: +0.3% yoy/+2.5% yoy previous: +0.3% yoy/+2.5% yoy PCE price index / core rate PROGNOSE: +0.3% yoy/+2.7% yoy PREV: +0.3% yoy/+2.6% yoy

14:00 DE: ECB Governing Council member Nagel, participation in panel discussion on "Inflation expectations and reality: implications for the last mile of disinflation"

15:00 US: Consumer Sentiment Index Uni Michigan (2nd survey) March PROGNOSIS: 57.9 1st survey: 57.9 previous: 64.7

Analyst updates, 15.11. 👇🏼

⬆️⬆️⬆️

- JEFFERIES raises the price target for ASML from EUR 760 to EUR 840. Buy. $ASML (-2,09 %)

- RBC raises the price target for TESLA from USD 249 to USD 313. Outperform. $TSLA (-9,97 %)

- JPMORGAN raises the price target for WALT DISNEY from USD 125 to USD 128. Overweight. $DIS (-6,12 %)

- JPMORGAN raises the price target for SIEMENS from EUR 215 to EUR 230. Overweight. $SIE (-7,45 %)

- BARCLAYS raises the target price for SIEMENS ENERGY from EUR 21 to EUR 35. Equal-Weight. $ENR (-9,65 %)

- LBBW raises the target price for EON from EUR 13.80 to EUR 13.90. Buy. $EOAN (-6,15 %)

- HAUCK AUFHÄUSER IB raises the target price for ADESSO from EUR 80 to EUR 85. Hold. $ADN1 (-3,88 %)

- DEUTSCHE BANK RESEARCH raises the target price for BURBERRY from GBP 7.40 to GBP 8.60. Hold. $BRBY (-6,32 %)

- BERENBERG raises the price target for TALANX from EUR 76.20 to EUR 91.10. Buy. $TLX (-7,19 %)

- BERENBERG raises the price target for HAPAG-LLOYD from EUR 163 to EUR 169. Hold. $HLAG (-7,03 %)

⬇️⬇️⬇️

- JPMORGAN lowers the price target for BAYER from EUR 34 to EUR 25. Neutral. $BAYN (-6,12 %)

- SANTANDER downgrades SHELL from Neutral to Outperform and lowers target price from GBP 30.50 to GBP 30. $SHEL (-7,19 %)

- WARBURG RESEARCH lowers the price target for SECUNET from EUR 216 to EUR 210. Buy. $YSN (-9,92 %)

- METZLER lowers the price target for SIXT-STÄMME from EUR 105 to EUR 95. Buy. $SIX2 (-6,59 %)

- ODDO BHF lowers the target price for MERCK KGAA from EUR 187 to EUR 176. Outperform. $MRK (-4,87 %)

- METZLER lowers the price target for SMA SOLAR from EUR 20 to EUR 16. Hold. $S92 (-5,01 %)

- DEUTSCHE BANK RESEARCH lowers the price target for GRENKE from EUR 28 to EUR 24. Buy. $GLJ (-4,51 %)

- BERENBERG lowers the target price for K+S from EUR 15.70 to EUR 14.70. Buy. $SDF (-1,01 %)

- BERENBERG lowers the price target for AUMANN from EUR 17 to EUR 14.50. Hold. $AAG (-2,27 %)

- BERENBERG lowers the price target for DERMAPHARM from EUR 58 to EUR 50. Buy. $DMP (-1,73 %)

- BARCLAYS lowers the price target for SYMRISE from EUR 123 to EUR 115. Equal-Weight. $SY1 (+0,31 %)

Summary Earnings, 14.11. 👇🏼

Siemens AG Q4 24 Earnings: $SIE (-7,45 %)

- Orders At 22.93Bln Euros (est 21.36 Bln Euros)

- Revenue Rising 1% To 20.81 Bln Euros (est 20.77 Bln Euros)

- Profit 3.12 Bln Euros (est 3.0 Bln Euros)

- Net Income Of 1.90 Bln Euros (est 1.80 Bln Euros)

Swiss Re Q3 24 Earnings: $SREN (-6,98 %)

- Net Income Of $2.2 Billion For The First Nine Months Of 2024

- 9m Return On Investments (ROI) Of 3.9%; Recurring Income Yield Of 4.0%

- Return On Equity (ROE) Of 13.4% For First Nine Months Of Year

- Still Expects To Achieve A Group Net Income Of More Than $3 Billion For 2024

- Currently Expects Losses Resulting From Hurricane Milton To Be Less Than $300 Mln, Which Will Impact Group Results In Q4 2024

E.ON SE 9M 24 Earnings: $EOAN (-6,15 %)

- Adj EBIT EU4.37B, -23% (Y/Y)

- Sales EU56.28B, -19% (Y/Y)

- Still Sees FY Adj EBITDA EU8.8B To EU9B, (est EU8.94B)

- Still Sees FY Adj Net EU2.8B To EU3B (est 2.92B)

Deutsche Telekom AG Q3 24 Earnings: $DTE (-4,46 %)

- Net Income EUR 2.957B (est EUR 2.396B)

- Adjusted EBITDA AL EU11.10B (est 11.05B)

- Rev EU28.50B (est 28.39B)

- Sees FY Adj EBITDA Al About EU43B

ASML is sticking to its long-term goals and plans to increase sales to between 44 and 60 billion euros by 2030, with a gross margin of 56 to 60 percent. Despite the current difficult market conditions, ASML CEO Christophe Fouquet sees promising long-term prospects for the semiconductor industry, especially due to the AI trend. $ASML (-2,09 %)

Talanx expects a record profit of over 1.9 billion euros for 2024 and a surplus of over 2.1 billion euros for 2025. The profit increase will be supported by primary insurance and new targets are to be presented at the Capital Markets Day on December 11. $TLX (-7,19 %)

Nagarro increased sales by 3.7 percent to 242.9 million euros in the third quarter and adjusted EBITDA by a good eight percent to 34.6 million euros. The company is adjusting its revenue forecast for 2024 to 960 million euros and expects an EBITDA margin of over 14 percent. $NA9 (-1,74 %)

Adesso recorded an increase in turnover of 15 percent to 330 million euros in the third quarter and a 37 percent rise in operating profit to 38.9 million euros. Jörg Schroeder will step down as Chief Financial Officer on April 30, 2025; his successor will be Michael Knopp from January 15, 2025. $ADN1 (-3,88 %)

Dermapharm increases turnover in the first nine months by just under three percent to 890.1 million euros, while adjusted EBITDA falls slightly to just over 240 million euros. However, consolidated net income rose to just under 93 million euros, and the Group CEO is optimistic for the final quarter. $DMP (-1,73 %)

Energiekontor sees itself on course for its annual targets after nine months with an expected pre-tax result of EUR 30 to 70 million, although the upper end of the range will not be reached due to the below-average wind year. Three projects with 79 MW have already been commissioned this year and several more projects are currently being marketed. $EKT (-6 %)

The financial services provider MLP increased revenue by twelve percent to EUR 746 million in the first nine months and EBIT by almost half to EUR 66 million. The company confirms its forecast for 2024 with EBIT of between EUR 85 and 95 million and expects EBIT of EUR 100 to 110 million in 2025. $MLP (-6,63 %)

GFT Technologies is again lowering its annual targets and now expects revenue growth of 10 percent to around EUR 865 million and adjusted EBIT of around EUR 77 million. Profit before taxes is expected to fall to around EUR 65 million, as the environment remains challenging and momentum in the coming months will be lower than expected. $GFT (-10,68 %)

ProSiebenSat.1 is lowering its forecast for the year due to weak TV advertising revenues and expects an adjusted operating result of less than EUR 575 million. The Group plans to sell Flaconi and Verivox in order to invest in Joyn, programs and debt reduction. $PSM (-1,62 %)

Wacker Neuson is again lowering its annual targets and now expects revenue of EUR 2.2 to 2.3 billion and an EBIT margin of 5.5 to 6.5 percent. In the third quarter, the company reports a drop in revenue of over 20 percent and a 61 percent fall in EBIT. $WAC (-10,75 %)

Cewe confirms its annual targets with sales of between 770 and 820 million euros and an EBIT of 77 to 87 million euros, with the upper half of the ranges being targeted. The company generates most of its profits in the Christmas quarter and posts a marginally positive EBIT in the summer quarter, despite increased marketing expenditure. $CWC (-2,67 %)

Merck KGaA reports a 1.8 percent increase in sales to 5.3 billion euros in the third quarter, while the adjusted operating result rises by 12 percent to over 1.6 billion euros. CEO Belén Garijo announces that sales for 2024 are expected to be in the lower half of the previous range. $MRK (-4,87 %)

Bilfinger records revenue growth of 15 percent to just under EUR 1.3 billion in the third quarter and increases operating profit by 35 percent to EUR 76 million, supported by good demand and the latest acquisition. The Executive Board confirms the adjusted annual targets with an increase in revenue to EUR 4.8 to 5.2 billion for 2024, also taking into account a savings program and special effects from the integration of Stork. $GBF (-13,52 %)

K+S is revising its production forecast for 2024 downwards due to high sickness rates and now expects an operating result (EBITDA) of around EUR 540 million. In the third quarter, the company reports a decline in sales and EBITDA, with profits exceeding analysts' expectations but remaining below consensus estimates for the full year. $SDF (-1,01 %)

05.09.2024

AI hype subsides + Insider buying at Dermapharm in the 2-digit million range + German government wants to reduce stake in Commerzbank + Real estate stocks benefit from interest rate hopes

Investors in the technology sector continue to take profits at the beginning of the seasonally rather poor stock market month of September. The previous day, European sector stocks had already come under pressure in the wake of the New York Nasdaq stock exchange, where semiconductor stocks in particular were sold off. This trend continued in European trading on Wednesday. Chip stocks also corrected in Asia amid somewhat disillusioned hype surrounding artificial intelligence (AI). In New York, the semiconductor index SOX had slipped by almost eight percent the previous evening, which, according to one trader, was the biggest daily loss since the coronavirus outbreak in March 2020. The AI favorite alone, the Nvidia $NVDA (-7,25 %) had lost a good 280 billion US dollars in value in one day on Tuesday.

The pharmaceutical manufacturer Dermapharm $DMP (-1,73 %) recently had to contend with significant declines in sales in some cases after the coronavirus pandemic subsided. However, the outlook for the branded pharmaceuticals manufacturer's core operating business is now brightening again, as evidenced by recent insider purchases in the double-digit million euro range. Dermapharm is also attractively valued fundamentally with a P/E ratio26e of 13.4 and a dividend yield of 2.6 %.

The threat of a placement of shares by the German government has put the shares of Commerzbank $CBK (-6,01 %) shares on Wednesday, particularly at the start of trading. In the first few minutes, the Frankfurt-based bank's shares lost up to 4.4% in a weak market environment. However, with the gradual recovery of the DAX, they ultimately reduced their price loss to less than half. The state is planning its exit and wants to reduce its stake in a first step, according to the Federal Finance Agency. According to informed circles, sales of initially 3 to 5 percent are being discussed, reports the news agency Bloomberg.

German real estate stocks were among the best performers in the weak market on Wednesday. In addition to increasing hopes of interest rate cuts following recent weak economic data, a positive sector study by Kepler Cheuvreux provided support. Vonovia $VNA (-2,32 %) was one of the best performers in the leading Dax index thanks to a price increase of around 0.8 percent. In the MDax of medium-sized listed companies TAG Immobilien $TEG (+1,56 %) topped the list of winners with a plus of 3.2 percent, followed by LEG Immobilien $LEG (-0,28 %) and Aroundtown $AT1 (-8,29 %). Patrizia $PAT (-6,36 %) took the top spot in the small cap index SDax with an increase of around 2.5 percent.

Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Qualcomm USD 0.85

Quarterly figures / company dates USA / Asia

/

Quarterly figures / Company dates Europe

10:00 Volvo Car Corp Capital Markets Day

11:00 Compugroup Medical Capital Markets Day

Economic data

• 08:00 DE: New orders July seasonally adjusted FORECAST: -1.0% yoy previous: +3.9% yoy | Manufacturing turnover July FORECAST: n/a previous: -0.9% yoy
• 11:00 EU: Retail Sales July Eurozone FORECAST: +0.3% yoy previous: -0.3% yoy
• 14:15 US: ADP Labor Market Report August Private Sector Employment PROGNOSE: +140,000 jobs previous: +122,000 jobs
• 14:30 US: Initial jobless claims (week) FORECAST: 229,000 Previous: 231,000
• 14:30 US: Productivity ex-farm (2nd release) 2Q annualized PROGNOSE: +2.5% yoy 1st release: +2.3% yoy 1st quarter: +0.4% yoy Unit labor costs PROGNOSE: +0.8% yoy 1st release: +0.9% yoy 1st quarter: +3.8% yoy
• 15:45 US: Purchasing Managers' Index/PMI Service (2nd release) August FORECAST: 55.1 1st release: 55.2 previous: 55.0
• 16:00 US: ISM Non-Manufacturing Index August Forecast: 51.0 points Previous: 51.4 points
• 17:30 US: Presidential candidate Trump, speech at Economic Club of New York event

$DMP (-1,73 %)

2 Inside trading and perhaps a renewed cannabis hype. I'm invested 🫡

Source: https://www.reddit.com/r/Aktien/s/0wPsdHdGqr

(I know, not so trustworthy, but that's how I found out about it and informed myself).